FIVE ELEVEN PHARMA, INC.
68Ga-labeled PSMA-targeting PET imaging agent for prostate cancer detection
- Sector
- Biotech
- Total capital
- $1.9M
- Federal grants
- $1.9M
- 5 awards · 2017–2020
- Rank in peer group#82 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 12 pending · first 2019
- Rank in peer group#29 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$248K
- Federal grantHealth and Human S · Phase II · Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$853K
- Federal grantHealth and Human S · Phase II · Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer$299K
- Federal grantHealth and Human S · Phase I · Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer$225K
- Federal grantHealth and Human S · Phase I · A low-cost automated Gallium-68 drug preparation device for diagnostic PET imaging$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#82 · top 25%
- Granted patents#29 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 5 granted of 17- GrantedNovel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationUSPTOUS 12,544,463
- PendingProstate-specific Membrane Antigen (psma) Inhibitors As Diagnostic And Radionuclide Therapeutic AgentsUSPTOApplication 17605609
- GrantedNovel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationUSPTOUS 11,071,794
Show all 17 patent records
- Novel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationFeb 10, 2026 · US 12,544,463Granted
- Prostate-specific Membrane Antigen (psma) Inhibitors As Diagnostic And Radionuclide Therapeutic AgentsApr 28, 2022 · Application 17605609Pending
- Novel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationJul 27, 2021 · US 11,071,794Granted
- Novel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationFeb 9, 2021 · US 10,912,849Granted
- Urea-based Prostate Specific Membrane Antigen (psma) Inhibitors For Imaging And TherapyJun 23, 2020 · US 10,688,200Granted
- HBED-Bisphosphonates, Radiometal Conjugates and Their Use as Theranostic AgentsApr 9, 2019 · US 10,253,052Granted
- Radiopharmaceutical Labeling DeviceApplication 62466087Pending
- Urea-based Prostate Specific Membrane Antigen (psma) Inhibitors For Imaging And TherapyApplication PCTUS2016068327Pending
- Hbed-bisphosphonates, Radiometal Conjugates Thereof And Their Use As Theranostic AgentsApplication PCTUS2016041040Pending
- Hbed-bisphosphonates, Radiometal Conjugates Thereof And Their Use As Theranostic AgentsApplication 62320296Pending
- Urea-based Prostate Specific Membrane Antigen (psma) Inhibitors For Imaging And TherapyApplication 62273786Pending
- 68GA HBED-Bisphosphonates and Their Use as Imaging AgentsApplication 62189652Pending
- Prostate-specific Membrane Antigen (psma) Inhibitors As Diagnostic And Radionuclide Therapeutic AgentsApplication PCTUS2020030085Pending
- Prostate-specific Membrane Antigen (psma) Inhibitors As Diagnostic And Radionuclide Therapeutic AgentsApplication 62839085Pending
- Novel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationApplication PCTUS2018034691Pending
- Radiopharmaceutical Labeling DeviceApplication PCTUS2018019894Pending
- Novel Deuterium Substituted Positron Emission Tomography (pet) Imaging Agents And Their Pharmacological ApplicationApplication 62513217Pending
Related companies, and why
- Gate BioscienceSimilar federal contract value in Biotech · null in contracts
- InsitroSimilar federal contract value in Biotech · null in contracts
- Nurix TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Z BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Antios Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- aTYR PHARMA INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .